Fig. 7

Clinical relevance of the NAT10-ITGB5-focal adhesion axis in the PNI of PDAC. (A-B) Representative image (A) and quantification (B) of the DRG model treated with the small-molecule inhibitor Remodelin (Rem), FAK inhibitor defactinib (DFN), and a combination of Rem and DFN. Scale bar: 200 μm. n = 5. (C) Schematic illustration of KPC tumor cells in the sciatic nerve of C57/Bl6 mice. (D) Representative immunofluorescent image of PNI in the sciatic nerve from the above groups. S100B, Schwann cells; CK19, PDAC cells. Scale bar: 200 μm. (E) Percentage of CK19-positive PDAC cells in the sciatic nerve from (D). n = 5. (F-G) Representative mIHC images (F) and statistical analysis (G) of ITGB5 expressed in CK19-positive cells of PDAC tissues from patients with NAT10-high or NAT10-low PDAC (revealed by IHC). Scale bar (left): 500 μm. Scale bar (middle and right): 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001. (B), and (E) One-way ANOVA. (G), unpaired Student’s test